{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T11:37:35Z","timestamp":1791805055827,"version":"4.3.4"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T00:00:00Z","timestamp":1683849600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T00:00:00Z","timestamp":1683849600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100015790","name":"Education Department of Ningxia Hui Autonomous Region","doi-asserted-by":"publisher","award":["2021BEG03036"],"award-info":[{"award-number":["2021BEG03036"]}],"id":[{"id":"10.13039\/100015790","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1007\/s00277-023-05255-w","type":"journal-article","created":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T14:03:15Z","timestamp":1683900195000},"page":"1789-1799","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Efficacy and safety-related factors of BTK inhibitors as a bridge to CAR-T therapy in R\/R FL"],"prefix":"10.1007","volume":"102","author":[{"given":"Xiupeng","family":"Ye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuemei","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Mu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meijing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuicui","family":"Lyu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeqiong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Mou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3646-4953","authenticated-orcid":false,"given":"Qi","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,12]]},"reference":[{"issue":"6","key":"5255_CR1","doi-asserted-by":"publisher","first-page":"443","DOI":"10.3322\/caac.21357","volume":"66","author":"LR Teras","year":"2016","unstructured":"Teras LR, Desantis CE, Cerhan JR et al (2016) 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin 66(6):443\u2013459","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"5255_CR2","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1002\/ajh.24937","volume":"93","author":"A Freedman","year":"2018","unstructured":"Freedman A (2018) Follicular lymphoma: 2018 update on diagnosis and management. Am J Hematol 93(2):296\u2013305","journal-title":"Am J Hematol"},{"key":"5255_CR3","first-page":"1070","volume":"62","author":"T Kobayashi","year":"2021","unstructured":"Kobayashi T (2021) The current therapeutic landscape for follicular lymphoma. Rinsho Ketsueki 62:1070\u20131076","journal-title":"Rinsho Ketsueki"},{"key":"5255_CR4","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow SH, Campo E, Pileri SA et al (2016) The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127:2375\u20132390","journal-title":"Blood"},{"key":"5255_CR5","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1111\/bjh.15816","volume":"185","author":"C Rusconi","year":"2019","unstructured":"Rusconi C, Anastasia A, Chiarenza A et al (2019) Outcome of transformed follicular lymphoma worsens according to the timing of transformation and to the number of previous therapies A retrospective multicenter study on behalf of Fondazione Italiana Linfomi (FIL). Br J Haematol 185:713\u2013717","journal-title":"Br J Haematol"},{"key":"5255_CR6","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1002\/cam4.1918","volume":"8","author":"F Lansigan","year":"2019","unstructured":"Lansigan F, Barak L, Pitcher B et al (2019) The prognostic significance of PFS24 in follicular lymphoma following firstline immunotherapy: a combined analysis of 3 CALGB trials. Cancer Med 8:165\u2013173","journal-title":"Cancer Med"},{"key":"5255_CR7","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","volume":"33","author":"C Casulo","year":"2015","unstructured":"Casulo C, Byrtek M, Dawson KL et al (2015) Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study. J Clin Oncol 33:2516\u20132522","journal-title":"J Clin Oncol"},{"issue":"1","key":"5255_CR8","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","volume":"20","author":"FL Locke","year":"2019","unstructured":"Locke FL, Ghobadi A, Jacobson CA et al (2019) Long-term safety and activity of axicabtagene ciloleucel in refractory large B cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1\u20132 trial. Lancet Oncol 20(1):31\u201342","journal-title":"Lancet Oncol"},{"issue":"8","key":"5255_CR9","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1182\/blood-2018-04-839217","volume":"132","author":"VA Chow","year":"2018","unstructured":"Chow VA, Shadman M, Gopal AK (2018) Translating anti-CD19 CAR T cell therapy into clinical practice for relapsed\/refractory diffuse large B cell lymphoma. Blood 132(8):777\u2013781","journal-title":"Blood"},{"issue":"1","key":"5255_CR10","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster SJ, Bishop MR, Tam CS et al (2019) Tisagenlecleucel in adult relapsed or refractory diffuse large B cell lymphoma. N Engl J Med 380(1):45\u201356","journal-title":"N Engl J Med"},{"issue":"26","key":"5255_CR11","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL et al (2017) Axicabtagene ciloleucel CAR T cell therapy in refractory large B cell lymphoma. N Engl J Med 377(26):2531\u20132544","journal-title":"N Engl J Med"},{"key":"5255_CR12","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude SL, Laetsch TW, Buechner J et al (2018) Tisagenlecleucel in children and young adults with B cell lymphoblastic leukemia. N Engl J Med 378:439\u2013448","journal-title":"N Engl J Med"},{"key":"5255_CR13","unstructured":"US Food and Drug Administration (2021) FDA grants accelerated approval to axicabtagene ciloleucel for relapsed or refractory follicular lymphoma.\u00a0https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-grantsaccelerated-approval-axicabtagene-ciloleucel-relapsed-or-refractoryfollicular-lymphoma"},{"issue":"7","key":"5255_CR14","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1182\/blood.2019000905","volume":"134","author":"VH Alexandre","year":"2019","unstructured":"Alexandre VH, Jordan G, Kevin AH et al (2019) High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell immunotherapy. Blood 134(7):636\u2013640","journal-title":"Blood"},{"issue":"2","key":"5255_CR15","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/s41591-021-01622-0","volume":"28","author":"HF Nathan","year":"2022","unstructured":"Nathan HF, Michael D, Martin D et al (2022) Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial. Nat Med 28(2):325\u2013332","journal-title":"Nat Med"},{"key":"5255_CR16","unstructured":"National Comprehensive Cancer Network (2011) NCCN clinical practice guidelines in oncology (NCCN guidelines). Central Nervous System Cancers Version 2:19-21"},{"issue":"27","key":"5255_CR17","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF et al (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32(27):3059\u20133068","journal-title":"J Clin Oncol"},{"issue":"5","key":"5255_CR18","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","volume":"104","author":"P Solal-Celigny","year":"2004","unstructured":"Solal-Celigny P, Roy P, Colombat P et al (2004) Follicular lymphoma international prognostic index. Blood 104(5):1258\u20131265","journal-title":"Blood"},{"issue":"27","key":"5255_CR19","doi-asserted-by":"publisher","first-page":"4555","DOI":"10.1200\/JCO.2008.21.3991","volume":"27","author":"M Federico","year":"2009","unstructured":"Federico M, Bellei M, Marcheselli L et al (2009) Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol 27(27):4555\u20134562","journal-title":"J Clin Oncol"},{"issue":"2","key":"5255_CR20","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","volume":"124","author":"DW Lee","year":"2014","unstructured":"Lee DW, Gardner R, Porter DL et al (2014) Current concepts in the diagnosis and management of cytokine release syndrome. Blood 124(2):188\u2013195","journal-title":"Blood"},{"issue":"4","key":"5255_CR21","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL et al (2019) ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant 25(4):625\u2013638","journal-title":"Biol Blood Marrow Transplant"},{"key":"5255_CR22","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1200\/JCO.2018.79.3083","volume":"36","author":"JW Friedberg","year":"2018","unstructured":"Friedberg JW (2018) Progress in advanced-stage follicular lymphoma. J Clin Oncol 36:2363\u20132365","journal-title":"J Clin Oncol"},{"issue":"4","key":"5255_CR23","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1111\/bjh.15149","volume":"184","author":"BK Link","year":"2019","unstructured":"Link BK, Day BM, Zhou X et al (2019) Second-line and subsequent therapy and outcomes for follicular lymphoma in the United States: data from the observational National Lymphocare Study. Br J Haematol 184(4):660\u2013663","journal-title":"Br J Haematol"},{"issue":"5","key":"5255_CR24","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/S1470-2045(21)00145-5","volume":"22","author":"MJ Matasar","year":"2021","unstructured":"Matasar MJ, Capra M, \u00d6zcan M et al (2021) Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, Phase 3 trial. Lancet Oncol 22(5):678\u2013689","journal-title":"Lancet Oncol"},{"issue":"11","key":"5255_CR25","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1200\/JCO.18.00915","volume":"37","author":"IW Flinn","year":"2019","unstructured":"Flinn IW, Miller CB, Ardeshna KM et al (2019) DYNAMO: a phase II study of duvelisib (IPI-145) in patients with refractory indolent non-hodgkin lymphoma. J Clin Oncol 37(11):912\u2013922","journal-title":"J Clin Oncol"},{"issue":"15","key":"5255_CR26","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1200\/JCO.20.03433","volume":"39","author":"NH Fowler","year":"2021","unstructured":"Fowler NH, Samaniego F, Jurczak W et al (2021) Umbralisib, a dual PI3K\u03b4\/CK1\u03b5 inhibitor in patients with relapsed or refractory indolent lymphoma. J Clin Oncol 39(15):1609\u20131618","journal-title":"J Clin Oncol"},{"key":"5255_CR27","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1182\/blood-2017-09-804641","volume":"131","author":"NL Bartlett","year":"2018","unstructured":"Bartlett NL, Costello BA, Laplant BR et al (2018) Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial. Blood 131:182\u2013190","journal-title":"Blood"},{"issue":"Supplement1","key":"5255_CR28","first-page":"40","volume":"136","author":"C Jacobson","year":"2020","unstructured":"Jacobson C, Chavez JC, Sehgal AR et al (2020) Primary analysis of zuma-5: a phase 2 study of axicabtagene ciloleucel (Axi-Cel) in patients with relapsed\/refractory (R\/R) indolent non-Hodgkin lymphoma (iNHL). Blood 136(Supplement1):40\u201341","journal-title":"Blood"},{"issue":"11","key":"5255_CR29","doi-asserted-by":"publisher","first-page":"4051","DOI":"10.1111\/cas.14638","volume":"111","author":"M Liu","year":"2020","unstructured":"Liu M, Wang X, Li Z et al (2020) Synergistic effect of ibrutinib and CD19 CAR-T cells on Raji cells in vivo and in vitro. Cancer Sci 111(11):4051\u20134060","journal-title":"Cancer Sci"},{"issue":"7","key":"5255_CR30","doi-asserted-by":"publisher","first-page":"2642","DOI":"10.1111\/cas.14915","volume":"112","author":"M Liu","year":"2021","unstructured":"Liu M, Deng H, Juan Mu et al (2021) Ibrutinib improves the efficacy of anti-CD19-CAR T cell therapy in patients with refractory non-Hodgkin\u2019s lymphoma. Cancer Sci 112(7):2642\u20132651","journal-title":"Cancer Sci"},{"issue":"3","key":"5255_CR31","doi-asserted-by":"publisher","first-page":"327","DOI":"10.17219\/acem\/145948","volume":"31","author":"Mu Juan","year":"2022","unstructured":"Juan Mu, Liu M, Wang J et al (2022) Successful treatment of second-time CAR-T 19 therapy after failure of first-time CAR-T 19 and ibrutinib therapy in relapsed mantle cell lymphoma. Adv Clin Exp Med 31(3):327\u2013335","journal-title":"Adv Clin Exp Med"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05255-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-023-05255-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05255-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T06:05:16Z","timestamp":1686549916000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-023-05255-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,12]]},"references-count":31,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["5255"],"URL":"https:\/\/doi.org\/10.1007\/s00277-023-05255-w","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,12]]},"assertion":[{"value":"31 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Medical Ethics Committee of the Tianjin First Center Hospital (Tianjin, China) (approved no. of ethic committee: 2015002X and 2018N105KY). Informed consent was obtained from the participants. The patients agreed to participate in our clinical trials. They agreed to the use of their data for our study. All the data and material have been performed in accordance with the Declaration of Helsinki and conformed to relevant aspects of the ARRIVE guidelines. This Clinical trial is registered at  as <i>ChiCTR-ONN-16009862<\/i> and  as <i>ChiCTR1800019622<\/i>.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"This is not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}